Dermavant Announces First Patient Dosed in Phase 2a Clinical Trial of Topical Dual JAK/Syk Inhibitor Cerdulatinib for Vitiligo

Ads

You May Also Like

Key Measure of Precipio’s Pathology Sales Growth 4X Prior Quarter

NEW HAVEN, Conn., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Precipio, Inc. (NASDAQ:PRPO), announced today ...

CytomX Therapeutics Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., July 10, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), ...

American Kidney Fund Appoints Five New Members to Board of Trustees

ROCKVILLE, Maryland, March 02, 2018 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF), the ...